{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:53:21Z","timestamp":1789502001166,"version":"build-2803163510"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Conditioning bifunctional agent, busulfan, is commonly used on children before hematopoietic stem cell transplantation. Currently, at the Ramathibodi hospital, Bangkok, Thailand, initial dosing is calculated according to age and body surface area, and 7 samples per day are used for therapeutic drug monitoring (TDM). This study aimed to identify the best strategies for individual dosages a priori from patient characteristics and a posteriori based on TDM.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>The pharmacokinetic data set consisted of 2018 plasma concentrations measured in 135 Thai (n = 135) pediatric patients (median age = 8 years) and were analyzed using a population approach.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Body weight, presence of malignant disease, and genetic polymorphism of <jats:italic toggle=\"yes\">Glutathione S-transferase Alpha-1<\/jats:italic> (<jats:italic toggle=\"yes\">GSTA1<\/jats:italic>) were predictors of clearance. The optimum sampling times for TDM concentration measurements were 0.25, 2, and 5 hours after a 3-hour infusion. This was sufficient to obtain a Bayesian estimate of clearance a posteriori. Simulations showed the poor performance of a priori formula-based dose calculations with 90% of patients demonstrating a 69%\u2013151% exposure interval around the target. This interval shrank to 85%\u2013124% if TDM was carried out only at day 1 and to 90%\u2013116% with TDM at days 1 and 3.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>This comprehensive study reinforces the interest of TDM in managing interindividual variability in busulfan exposure. Therapeutic drug monitoring can reliably be implemented from 3 samples using the Bayesian approach, preferably over 2 days. If using the latter is not possible, the formulas developed herein could present an alternative in Thai patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001225","type":"journal-article","created":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T17:00:06Z","timestamp":1715965206000},"page":"778-785","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Model-Informed Precision Dosing of Intravenous Busulfan in Thai Pediatrics Undergoing Hematopoietic Stem Cell Transplantation"],"prefix":"10.1097","volume":"46","author":[{"given":"Apichaya","family":"Puangpetch","sequence":"first","affiliation":[{"name":"Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"Thomas","sequence":"additional","affiliation":[{"name":"Laboratoire de Pharmacologie, Oncopole Claudius-Regaud, Institut Universitaire du Cancer de Toulouse Oncopole, Centre de Recherche en Canc\u00e9rologie de Toulouse, INSERM U1037, Universit\u00e9 Paul Sabatier, Toulouse, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usanarat","family":"Anurathapan","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samart","family":"Pakakasama","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suradej","family":"Hongeng","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiratha","family":"Rachanakul","sequence":"additional","affiliation":[{"name":"Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand;"},{"name":"Laboratory for Pharmacogenomics, Clinical Pathology, Somdetch Phra Debharatana Medical Centre, Ramathibodi Hospital, Bangkok, Thailand;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santirhat","family":"Prommas","sequence":"additional","affiliation":[{"name":"Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand;"},{"name":"Laboratory for Pharmacogenomics, Clinical Pathology, Somdetch Phra Debharatana Medical Centre, Ramathibodi Hospital, Bangkok, Thailand;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nutthan","family":"Nuntharadthanaphong","sequence":"additional","affiliation":[{"name":"Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand;"},{"name":"Laboratory for Pharmacogenomics, Clinical Pathology, Somdetch Phra Debharatana Medical Centre, Ramathibodi Hospital, Bangkok, Thailand;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9tienne","family":"Chatelut","sequence":"additional","affiliation":[{"name":"Laboratoire de Pharmacologie, Oncopole Claudius-Regaud, Institut Universitaire du Cancer de Toulouse Oncopole, Centre de Recherche en Canc\u00e9rologie de Toulouse, INSERM U1037, Universit\u00e9 Paul Sabatier, Toulouse, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chonlaphat","family":"Sukasem","sequence":"additional","affiliation":[{"name":"Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand;"},{"name":"Laboratory for Pharmacogenomics, Clinical Pathology, Somdetch Phra Debharatana Medical Centre, Ramathibodi Hospital, Bangkok, Thailand;"},{"name":"Pharmacogenomics Clinic, Bumrungrad Genomic Medicine Institute, Bumrungrad International Hospital, Bangkok, Thailand;"},{"name":"Research and Development Laboratory, Bumrungrad International Hospital, Bangkok, Thailand;"},{"name":"Faculty of Pharmaceutical Sciences, Burapha University, Chonburi, Thailand; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e9licien","family":"Le Louedec","sequence":"additional","affiliation":[{"name":"Laboratoire de Pharmacologie, Oncopole Claudius-Regaud, Institut Universitaire du Cancer de Toulouse Oncopole, Centre de Recherche en Canc\u00e9rologie de Toulouse, INSERM U1037, Universit\u00e9 Paul Sabatier, Toulouse, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,5,14]]},"reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40262-020-00947-2","article-title":"Review of the pharmacokinetics and pharmacodynamics of intravenous busulfan in paediatric patients","volume":"60","author":"Lawson","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/sj.bmt.1703612","article-title":"Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation","volume":"30","author":"McCune","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"e526","DOI":"10.1016\/S2352-3026(16)30114-4","article-title":"Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis","volume":"3","author":"Bartelink","year":"2016","journal-title":"Lancet Haematol"},{"key":"R4-20250603","first-page":"225","article-title":"Association of busulfan area under the curve with veno-occlusive disease following BMT","volume":"17","author":"Dix","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/s41409-018-0281-7","article-title":"Maximal concentration of intravenous busulfan as a determinant of veno-occlusive disease: a pharmacokinetic-pharmacodynamic analysis in 293 hematopoietic stem cell transplanted children","volume":"54","author":"Philippe","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.bbmt.2007.10.028","article-title":"High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen","volume":"14","author":"Geddes","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1002\/psp4.12683","article-title":"Precision dosing of intravenous busulfan in pediatric hematopoietic stem cell transplantation: results from a multicenter population pharmacokinetic study","volume":"10","author":"Ben Hassine","year":"2021","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00280-021-04288-0","article-title":"Evaluation of two software using Bayesian methods for monitoring exposure and dosing once-daily intravenous busulfan in paediatric patients receiving haematopoietic stem cell transplantation","volume":"88","author":"Lawson","year":"2021","journal-title":"Cancer Chemother Pharmacol"},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/sj.bmt.1703229","article-title":"Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipients","volume":"28","author":"Sandstr\u00f6m","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1182\/blood-2004-02-0414","article-title":"Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS","volume":"104","author":"de Lima","year":"2004","journal-title":"Blood"},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.bbmt.2007.09.015","article-title":"Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation","volume":"14","author":"Bartelink","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3390\/pharmaceutics14020401","article-title":"Effect of GSTA1 variants on busulfan-based conditioning regimen prior to allogenic hematopoietic stem-cell transplantation in pediatric Asians","volume":"14","author":"Nguyen","year":"2022","journal-title":"Pharmaceutics"},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1097\/01.cad.0000231482.15277.48","article-title":"Once-daily intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics and early clinical outcomes","volume":"17","author":"Zwaveling","year":"2006","journal-title":"Anticancer Drugs"},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.bbmt.2011.11.025","article-title":"Highly variable pharmacokinetics of once-daily intravenous busulfan when combined with fludarabine in pediatric patients: phase I clinical study for determination of optimal once-daily busulfan dose using pharmacokinetic modeling","volume":"18","author":"Lee","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"e28603","DOI":"10.1002\/pbc.28603","article-title":"New dosing nomogram and population pharmacokinetic model for young and very young children receiving busulfan for hematopoietic stem cell transplantation conditioning","volume":"67","author":"Poinsignon","year":"2020","journal-title":"Pediatr Blood Cancer"},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/psp4.12467","article-title":"Quantitative systems pharmacology and physiologically-based pharmacokinetic modeling with mrgsolve: a hands-on tutorial","volume":"8","author":"Elmokadem","year":"2019","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/psp4.12689","article-title":"Easy and reliable maximum a posteriori Bayesian estimation of pharmacokinetic parameters with the open-source R package mapbayr","volume":"10","author":"Le Louedec","year":"2021","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"R21-20250603","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1002\/psp4.12809","article-title":"Population pharmacokinetic model for once-daily intravenous busulfan in pediatric subjects describing time-associated clearance","volume":"11","author":"Lawson","year":"2022","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"R22-20250603","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1159\/000028359","article-title":"Role of oxidative stress and glutathione in busulfan toxicity in cultured murine hepatocytes","volume":"60","author":"DeLeve","year":"2000","journal-title":"Pharmacology"},{"key":"R23-20250603","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.bbmt.2010.06.017","article-title":"Linearity and stability of intravenous busulfan pharmacokinetics and the role of glutathione in busulfan elimination","volume":"17","author":"Almog","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"R24-20250603","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.2217\/pgs.13.159","article-title":"Effect of genetic variants GSTA1 and CYP39A1 and age on busulfan clearance in pediatric patients undergoing hematopoietic stem cell transplantation","volume":"14","author":"ten Brink","year":"2013","journal-title":"Pharmacogenomics"},{"key":"R25-20250603","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S0090-9556(25)07498-7","article-title":"Busulfan conjugation by glutathione S-transferases alpha, mu, and pi","volume":"24","author":"Czerwinski","year":"1996","journal-title":"Drug Metab Dispos"},{"key":"R26-20250603","first-page":"1015","article-title":"A limited sampling strategy for pharmacokinetic directed therapy with intravenous busulfan","volume":"24","author":"Vaughan","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"R27-20250603","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.bbmt.2008.03.002","article-title":"IV busulfan dose individualization in children undergoing hematopoietic stem cell transplant: limited sampling strategies","volume":"14","author":"Dupuis","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"R28-20250603","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/FTD.0000000000000276","article-title":"Accurately achieving target busulfan exposure in children and adolescents with very limited sampling and the BestDose software","volume":"38","author":"Neely","year":"2016","journal-title":"Ther Drug Monit"},{"key":"R29-20250603","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s40262-020-00877-z","article-title":"Intra-individual pharmacokinetic variability of intravenous busulfan in hematopoietic stem cell-transplanted children","volume":"59","author":"Marsit","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"R30-20250603","doi-asserted-by":"crossref","first-page":"834773","DOI":"10.3389\/fped.2022.834773","article-title":"Can first-dose therapeutic drug monitoring predict the steady state area under the blood concentration-time curve of busulfan in pediatric patients undergoing hematopoietic stem cell transplantation?","volume":"10","author":"Alsultan","year":"2022","journal-title":"Front Pediatr"},{"key":"R31-20250603","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/s41409-023-01971-z","article-title":"Busulfan target exposure attainment in children undergoing allogeneic hematopoietic cell transplantation: a single day versus a multiday therapeutic drug monitoring regimen","volume":"58","author":"Bogn\u00e0r","year":"2023","journal-title":"Bone Marrow Transplant"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001225","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:12:57Z","timestamp":1748970777000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,14]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001225","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,14]]},"assertion":[{"value":"2023-12-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-26","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}